One large “zap” for painful bone metastases is enough

In 2011, the American Society for Radiation Oncology (ASTRO) issued a consensus statement as part of its “Choosing Wisely” campaign that found that 30 Gy in 10 fractions (treatments), 20 Gy in 5 fractions, and 8 Gy in 1 fraction all gave equivalent pain relief. … READ MORE …

PROs and HRQoL among patients participating in the LATITUDE trial

A newly published paper in The Lancet Oncology has provided early data from the LATITUDE trial on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) for men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer. … READ MORE …

TAPS as a side effect of taxane-based chemotherapy in men with advanced prostate cancer

TAPS stands for “taxane acute pain syndrome”. It is a recognized side effect of treatment with taxanes like docetaxel and it is usually characterized by muscular pain (myalgia) and joint pain (arthralgia) that starts about 24 to 48 hours after taxane treatment and then lasts for up to about 7 days. … READ MORE …

Major trial confirms value of zoledronic acid dosed every 3 months in preventing pain, SREs

An interesting paper that we managed to miss at the recent annual meeting of the American Society of Clinical Oncology (ASCO) provided the results of a large, randomized clinical trial of the use of zoledronic acid, carried out by the Cancer and Leukemia Group B cooperative trial group. … READ MORE …

A genetic driver of pain in prostate cancer … and other cancers too?

According to a newly published paper in the journal Pain, the presence of a particular genetic marker in cancer cells may be a key factor in risk for cancer-related pain. … READ MORE …

Music (plus lidocaine) soothes the savaged male

A small, randomized, pilot study has shown that music (along with some lidocaine) reduces the anxiety, pain, and dissatisfaction of men having a TRUS-guided biopsy compared to the lidocaine alone. … READ MORE …

Penile pain/urethral discomfort after radical prostatectomy

It comes as no surprise that there is some urethral “discomfort” experienced by patients with an indwelling urethral catheter after a radical prostatectomy (regardless of the type of surgery), and that for some patients there can be a degree of significant penile pain until the catheter is removed (usually within about 8 to 10 days). … READ MORE

When is radiopharmaceutical therapy most appropriately initiated in men with mCRPC?

A newly published paper by a team of Italian researchers has added a wrinkle to the critical questions about the most effective current and future forms of sequential therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Single- vs. multi-fraction radiation therapy for metastatic, bone-related cancer pain

Data published in 2005 and later have clearly shown that — for most patients — single-fraction radiation therapy (e.g., a single dose of 8 Gy) is better than multi-fraction radiation therapy (e.g., 30 Gy given over 10 treatments) for the treatment of bone pain consequent to metastatic cancer that has spread into the bones (in prostate cancer and other forms of cancer). … READ MORE …

Pain still under-treated in many men with mCRPC (even at the best centers)

Back in the 1970s and 1980s, before the availability of the PSA test (with all its flaws and benefits), it used to be the case that pain was one of the commonest symptoms leading to a diagnosis of prostate cancer … because the majority of men only got diagnosed when they already had advanced, metastatic disease. … READ MORE …

FDA approves ExAblate technology to treat late stage bone pain

According to a media release issued yesterday, The U. S. Food and Drug Administration has approved a form of MRI-guided, focused ultrasound therapy for the treatment of pain associated with metastatic cancer to bone. … READ MORE …

Tamoxifen in prevention/management of gynecomastia and related, antiandrogen-induced side effects

According to a new, systematic review of data from four independently conducted clinical trials, tamoxifen may be the most effective agent for the management of breast events induced by treatment with non-steroidal antiandrogens (e.g., bicalutamide) in men with prostate cancer. … READ MORE …

Biopsy in D minor by Johann Sebastian you know who

A group of medical students and fellows at Duke University have shown that if you distract patients’ attention while they are having a prostate biopsy it can (at least to some extent) reduce the likelihood of patient reports of pain and anxiety associated with the procedure. … READ MORE …

Radionuclide therapy with strontium-89 for relief of metastatic bone pain

A new article on the OncologySTAT web site provides a summary of a presentation by Alain Pecking, MD, from the annual meeting of the International Society for Geriatric Oncology. … READ MORE …

Two phase III trials planned for cabozantinib in mCRPC

Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC): … READ MORE …